• Redx Announces First Patient Dosed in Phase 2a Trial for RXC007

    Read more
  • Redx Presents Preclinical Data Confirming Anti-Fibrotic Effects of RXC007 in Immune Mediated Models, and Final Phase 1 Safety Data

    Read more
  • Redx to Present Poster on Encouraging Preclinical Fibrosis Data for RXC007 at the 21st International Colloquium on Lung and Airway Fibrosis

    Read more
  • Redx to Present Preclinical Data Poster for RXC007 at the European Respiratory Society International Congress

    Read more
  • Redx to Present at Proactive One2One Virtual Investor Forum

    Read more
  • Redx Presents Encouraging Preclinical Data on the Potential of Porcupine and ROCK Inhibitors to Tackle Cancer-Associated Fibrosis

    Read more
  • Interim Results for the Six Months Ended 31 March 2022

    Read more
  • Redx to Present Preclinical Data on Three Proprietary Compounds at the Extracellular Matrix Pharmacology Congress

    Read more
  • Notice of Interim Results

    Read more
  • Jazz Pharmaceuticals and Redx Announce Pan-RAF Inhibitor JZP815 to Enter Clinical Development

    Read more